Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15336507 | 0.85 | AOC3 (0.40) | DPP4F2AOC3CTSDLMNA | |
| SCHEMBL15715609 | 0.74 | HTR2A (0.46) | AOC3GBA1 | |
| SCHEMBL2866367 | 0.72 | DPP4 (0.56) | DPP4F2AOC3LMNAADRA2A | |
| SCHEMBL28763539 | 0.72 | DPP4 (0.56) | DPP4F2AOC3LMNAADRA2A | |
| SCHEMBL6742099 | 0.72 | DPP4 (0.56) | DPP4F2AOC3LMNAADRA2A | |
| SCHEMBL14455234 | 0.72 | DPP4 (0.56) | DPP4F2AOC3LMNAADRA2A | |
| SCHEMBL10013666 | 0.72 | DPP4 (0.50) | DPP4F2AOC3CTSDLMNA | |
| SCHEMBL8459121 | 0.71 | DPP4 (0.48) | DPP4F2AOC3GBA1 | |
| SCHEMBL851654 | 0.69 | DPP4 (1.00) | DPP4F2LMNAADRA2AADRA2C | |
| SCHEMBL644767 | 0.69 | DPP4 (1.00) | DPP4F2LMNAADRA2AADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113941365-A | Temperature-sensitive catalyst for asymmetric hydrogen transfer reaction of aromatic ketone and preparation method thereof | 南开沧州渤海新区绿色化工研究有限公司 | 2022-01-18 | — | — | CN | claimed |
| EP-3544955-B1 | IMPROVED PROCESS FOR PREPARING ASTACENE | BASF SE (DE) | 2021-07-14 | — | — | EP | claimed |
| US-10836718-B2 | Process for preparing astacene | BASF SE (DE) | 2020-11-17 | — | — | US | claimed |
| EP-3544955-A1 | IMPROVED PROCESS FOR PREPARING ASTACENE | BASF SE (DE) | 2019-10-02 | — | — | EP | claimed |
| US-20190292147-A1 | IMPROVED PROCESS FOR PREPARING ASTACENE | BASF SE (DE) | 2019-09-26 | — | — | US | claimed |
| WO-2018095863-A1 | IMPROVED PROCESS FOR PREPARING ASTACENE | BASF SE (DE) | 2018-05-31 | — | — | WO | claimed |
| EP-2680697-A1 | PROCESS FOR THE PREPARATION OF AN OREXIN RECEPTOR ANTAGONIST | Merck Sharp & Dohme Corp. (US) | 2014-01-08 | — | — | EP | claimed |
| WO-2012148553-A1 | PROCESS FOR THE PREPARATION OF AN OREXIN RECEPTOR ANTAGONIST | MERCK SHARP & DOHME CORP. (US) | 2012-11-01 | — | — | WO | claimed |
| US-11401266-B2 | Process for the preparation of an orexin receptor antagonist | Merck Sharp & Dohme (UK) Ltd. (GB) | 2022-08-02 | — | — | US | disclosed |
| EP-3544955-B1 | IMPROVED PROCESS FOR PREPARING ASTACENE | BASF SE (DE) | 2021-07-14 | — | — | EP | disclosed |
| US-10836718-B2 | Process for preparing astacene | BASF SE (DE) | 2020-11-17 | — | — | US | disclosed |
| EP-3544955-A1 | IMPROVED PROCESS FOR PREPARING ASTACENE | BASF SE (DE) | 2019-10-02 | — | — | EP | disclosed |
| US-20190292147-A1 | IMPROVED PROCESS FOR PREPARING ASTACENE | BASF SE (DE) | 2019-09-26 | — | — | US | disclosed |
| CN-106083837-B | The preparation method of Yi Zhong oxazolidinones antibacterials and its intermediate | 浙江普洛得邦制药有限公司 | 2018-08-31 | — | — | CN | disclosed |
| WO-2018095863-A1 | IMPROVED PROCESS FOR PREPARING ASTACENE | BASF SE (DE) | 2018-05-31 | — | — | WO | disclosed |
| CN-104114539-B | Process for the stereoselective preparation of pyrazole carboxamides | 先正达参股股份有限公司 | 2016-10-12 | — | — | CN | disclosed |
| CN-103080118-B | Ruthenium-diamine complexe and the method for producing optically active compound | TAKASAGO INTERNATIONAL CORP. (JP) | 2016-05-11 | — | — | CN | disclosed |
| CN-102304007-B | Asymmetric catalytic hydrogenation reaction method of intra-annular N-alkylimine | CHINESE ACAD INST CHEMISTRY | 2014-01-29 | — | — | CN | disclosed |
| CN-1377342-A | Process for preparation of tricyclic amino alcohol derivatives | ASAHI CHEMICAL IND (JP) | 2002-10-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11401266-B2 | Process for the preparation of an orexin receptor antagonist | HCRTR2, HCRTR1, CRHR1 | DPP4 1558/4885F2 1667/4885AOC3 410/4885 |
| US-20190292147-A1 | IMPROVED PROCESS FOR PREPARING ASTACENE | ADH1A, COASY, SQLE | DPP4 3611/4885F2 91/4885AOC3 570/4885 |
| US-10836718-B2 | Process for preparing astacene | SQLE, ADH1A, ADH1C | DPP4 3980/4885F2 49/4885AOC3 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.